塞来昔布对重型颅脑损伤患者临床疗效及神经功能的影响  

Effects of celecoxib on clinical efficacy and neurological functions in patients with severe head injury

作　　者：张涛 张金玲[2] 王凤聚 崔福生 闫静波 刘登湘 陈树波 

机构地区：[1]河北医科大学附属邢台市人民医院神经外科,河北邢台054031 [2]邢台医学高等专科学校药学系,河北邢台054031

出　　处：《中国医院药学杂志》2017年第24期2471-2474,共4页Chinese Journal of Hospital Pharmacy

基　　金：河北省自然科学基金项目(编号:C2004000689);河北省博士基金项目(编号:05547008D-4);河北省科学技术与社会发展计划项目(编号:04276135)

摘　　要：目的:探讨塞来昔布对重型颅脑损伤患者临床疗效及神经功能的影响。方法:选取某院2014年1月-2016年12月重型颅脑损伤患者80例,并将其分为治疗组和对照组。对照组进行常规治疗,治疗组在对照组的基础上给予塞来昔布治疗。检测2组患者血清TNF-α、IL-1β水平变化。2组患者治疗7 d、14 d后行GCS评分,3个月后按GOS预后评分评定预后,治疗前及治疗3个月后Barthel指数评分,治疗期间清醒时间及意识恢复清醒情况。结果:治疗组患者治疗后IL-1β、TNF-α水平显著低于治疗前(P<0.05);治疗组患者治疗7 d、14 d后GCS评分均较治疗前明显增高(P<0.05),治疗组患者治疗结束及随访结束时GOS评分均明显高于对照组(P<0.05);治疗组患者治疗3个月后Barthel评分相较对照组显著提高(P<0.05);治疗组患者治疗期间清醒时间明显长于对照组(P<0.05);治疗组患者治疗期间意识恢复率明显高于对照组(P<0.05);治疗组患者治愈率较对照组显著升高(P<0.05),治疗组患者重残率与病死率较对照组显著降低(P<0.05)。结论:塞来昔布可改善重型颅脑损伤患者预后及日常生活能力,促进神经功能恢复、降低病死率,临床疗效确切。OBJECTIVE To investigate the effect of celecoxib on clinical efficacy and neurological functions in patients with severe craniocerebral injury.METHODS Totally 80 patients with severe craniocerebral injury were enrolled from January 2014 to December 2016 and divided into treatment group and control group.Patients in the control group were treated with conventional regimen.Patients in the treatment group were treated with celecoxib on the basis of the control group.Some parameters were determined in both groups,including changes of serum TNF-αand IL-1βlevels,GCS scores 7 d and 14 d after the treatment,GOS prognosis score 3 months later for evaluating outcome,Barthel index scores before treatment and 3 months after treatment,sober time during treatment and consciousness recovery time.RESULTS The levels of IL-1βand TNF-αafter treatment in the treatment group were significantly lower than those before treatment（P0.05）.The GCS scores of the treatment group were significantly higher than those of the control group before treatment 7 d and 14 d after treatment（P0.05）.Compared with control group,the GOS score of the treatment group was significantly higher at the end of treatment and during follow-up（P0.05）,Barthel score was significantly higher（P0.05）,the awake time was significantly longer（P0.05）,the recovery rate of consciousness was significantly higher（P0.05）,the cure rate of was significantly higher（P0.05）,the rates of severe disability and mortality were significantly lower（P0.05）.CONCLUSION Celecoxib can improve the prognosis and daily living capacity of patients with severe craniocerebral injury,promote nervous function recovery,reduce mortality,and has clinical efficacy.

关 键 词：塞来昔布 重型颅脑损伤 神经功能 临床疗效 

分 类 号：R651.1[医药卫生—外科学]